Back to Neurology




Spherix’s coverage of the migraine market tracks the impact of expanding therapeutic choice on migraine management. Broad coverage of both the acute and preventive segments allows Spherix to assess the interplay of market dynamics for the treatment of episodic and chronic migraine.

Services Available

Trending market evolution

  • Migraine – Specialist Perspective (US)

  • Migraine – PCP Perspective (US)

  • Migraine (EU)

Service Info

RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.

Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.

Sample Size and Frequency

US: quarterly report (n=100-200 respondents)

EU5: semiannual report (n=250 respondents)

Canada: semiannual report (n=50 respondents)

Exploring the patient journey

  • Preventive Treatment in Migraine (US)

Service Info

RealWorld Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

Report Methodology: Insights are based on patient level data gathered through collaboration with specialty physicians who provide details on clinical and non-clinical patient demographics, along with their rationale for treatment choices.

Sample Size and Frequency

US: annual patient chart audit (n=1,000 charts, n=200 physicians)

EU5: annual patient chart audit (n=1,250 charts, n=250 physicians)

Benchmarking New Brand Performance

  • AXS-07 (Axsome) in Acute Migraine (US)*

  • DHE Autoinjector (Amneal) in Acute Migraine (US)*

  • Nurtec ODT (Biohaven) in Migraine Prevention (US)

  • Qulipta (AbbVie) in Migraine Prevention (US)

  • Trudhesa (Impel) in Acute Migraine (US)

  • Zavegepant (Biohaven) in Acute Migraine (US)*

*Pending approvals and launch

Service Info

Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

Methodology: Insights are based on analyses of quantitative data collected from an online survey of physicians “in the trenches” recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents.

Sample Size and Frequency

Monthly KPI benchmarking (n=75 physicians)

Quarterly report (n=75 physicians)

Quarterly qualitative interviews (n=8 physicians)

Learn more about our services


Get more information on Migraine Coverage